In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Khositnithikul, Rommanee ^a   Tan Ariya, Peerapan ^a   Mungthin, Mathirut ^b  

^a Mahidol University   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYTOCHROME B; PROGUANIL; ANTIMALARIAL AGENT; PROTOZOAL PROTEIN;

ARTICLE; CODON; DNA SEQUENCE; DRUG ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; DRUG USE; ENDEMIC DISEASE; GENE MUTATION; GENETIC TRAIT; GENOTYPE; IC 50; IN VITRO STUDY; MALARIA; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; RADIOISOTOPE DISTRIBUTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THAILAND; TREATMENT FAILURE; ANIMAL; DRUG EFFECT; GENE; GENETICS; MALARIA FALCIPARUM; PARASITOLOGY;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; CODON; CYTOCHROMES B; DRUG RESISTANCE, MULTIPLE; GENES, PROTOZOAN; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTOZOAN PROTEINS; THAILAND;

EID: 40549103118     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-23     Document Type: Article

References (25)

1. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. S Vijaykadga C Rojanawatsirivej S Cholpol D Phoungmanee A Nakavej C Wongsrichanalai, Trop Med Int Health 2006 11 211 219 10.1111/j.1365-3156.2005.01557.x 16451346
2. Atovaquone-proguanil for treating uncomplicated malaria. A Osei-Akoto L Orton SP Owusu-Ofori, Cochrane Database Syst Rev 2005 4 CD004529 16235366
3. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. H Nakato R Vivancos PR Hunter, Antimicrob Chemother 2007 60 929 936 10.1093/jac/dkm337
4. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. IK Srivastava H Rottenberg AB Vaidya, J Biol Chem 1997 272 3961 3966 10.1074/jbc.272.52.33360 9020100
5. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. JJ Kessl KH Ha AK Merritt BB Lange P Hill B Meunier SR Meshnick BL Trumpower, J Biol Chem 2005 280 17142 17148 10.1074/jbc.M500388200 15718226
6. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. I Ittarat W Asawamahasakda SR Meshnick, Exp Parasitol 1994 79 50 56 10.1006/expr.1994.1058 8050525
7. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. I Srivastava A Vadiya, Antimicrob Agents Chemother 1999 43 1334 1339 10348748
8. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. QL Fivelman GA Butcher IS Adagu DC Warhurst G Pasvol, Malar J 2002 1 1 12057021 10.1186/1475-2875-1-1
9. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. B Schwobel M Alifrangis A Salanti T Jelinek, Malar J 2003 2 5 12665429 10.1186/1475-2875-2-5
10. Atovaquone/proguanil resistance in Africa: a case report. KP David M Alifrangis A Salanti LS Vestergaard A Ronn IB Bygbjerg, Scand J Infect Dis 2003 35 897 898 14723376
11. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. A Farnert J Lindberg P Gil G Swedberg Y Berqvist MM Thapar N Lindegardh S Berezcky A Bjorkman, BMJ 2003 326 628 629 12649236 10.1136/bmj.326.7390.628
12. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. E Schwartz S Bujanover KC Kain, Clin Infect Dis 2003 37 450 451 10.1086/375599 12884171
13. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. O Wichmann N Muehlberger T Jelinek M Alifrangis G Peyerl-Hoffmann M Muhlen MP Grobusch J Gascon A Matteelli H Laferl Z Bisoffi S Ehrhardt J Cuadros C Hatz I Gjorup P McWhinney J Beran S da Cunha M Schulze H Kollaritsch P Kern G Fry J Richter European Network on Surveillance of Imported Infectious Diseases, J Infect Dis 2004 190 1541 1546 10.1086/424469 15478057
14. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. S Kuhn MJ Gill KC Kain, Am J Trop Med Hyg 2005 72 407 409 15827276
15. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. L Musset B Pradines D Parzy R Durand P Bigot J Le Bras, J Antimicrob Chemother 2006 57 110 115 10.1093/jac/dki420 16319183
16. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. L Musset O Bouchaud S Matheron L Massias J Le Bras, Microbes Infect 2006 8 2599 2604 10.1016/j.micinf.2006.07. 011 16962361
17. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. M Korsinczky N Chen B Kotecka A Saul K Rieckmann Q Cheng, Antimicrob Agents Chemother 2000 44 2100 2108 10898682 10.1128/AAC.44.8.2100-2108.2000
18. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. S Krudsood SN Patel N Tangpukdee W Thanachartwet W Leowattana K Pornpininworakij AK Boggild S Looareesuwan KC Kain, Am J Trop Med Hyg 2007 76 655 658 17426165
19. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. CT Happi GO Gbotosho OA Folarin D Milner O Sarr A Sowunmi DE Kyle WK Milhous DF Wirth AM Oduola, Malar J 2006 5 82 17020611 10.1186/1475-2875-5-82
20. Human malaria parasites in continuous culture. W Trager JB Jensen, Science 1976 193 673 675 10.1126/science.781840 781840
21. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. RE Desjardins CJ Canfield JD Haynes JD Chulay, Antimicrob Agents Chemother 1979 16 710 718 394674
22. Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains. J Wooden EE Gould AT Paull CH Sibley, Exp Parasitol 1992 75 207 212 10.1016/0014-4894(92)90180-I 1516668
23. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. F Gay D Bustos B Traore C Jardinel M Southammavong L Ciceron MM Danis, Am J Trop Med Hyg 1997 56 315 317 9129535
24. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. A Berry A Senescau J Lelièvre F Benoit-Vical R Fabre B Marchou JF Magnaval, Trans R Soc Trop Med Hyg 2006 100 986 988 10.1016/j.trstmh.2006.02.004 16690094
25. Analyses of cytochrome b mutations in Plasmodium falciparum isolates in Thai-Myanmar border. Y Naoshima-Ishibashi M Iwagami S Kawazu S Looareesuwan S Kano, Travel Med Infect Dis 2007 5 132 134 10.1016/j.tmaid.2006.07.002 17298921